Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy

Summary

A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year

Timeline

Start

2022-07-01

Primary completion

2023-12-08

Completion

2027-12

Drugs

Indications